A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 45 - 100 |
| Updated: | 4/21/2016 |
| Start Date: | February 2006 |
| End Date: | December 2016 |
A Randomized, Open-Label, Parallel-Group, Multicentre, Phase II Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg With Anastrozole (ARIMIDEX™) 1 mg as First Line Hormonal Treatment for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
The purpose of this study is to compare the efficacy and tolerability of Faslodex
(fulvestrant) with Arimidex (anastrozole) in postmenopausal women with hormone receptor
positive advanced breast cancer.
(fulvestrant) with Arimidex (anastrozole) in postmenopausal women with hormone receptor
positive advanced breast cancer.
Inclusion Criteria:
- Confirmed hormone receptor positive advanced breast cancer, postmenopausal women
Exclusion Criteria:
- Previous treatment for advanced breast cancer (previous treatment for early breast
cancer is allowed).
We found this trial at
6
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials